New Delhi, Mar 28 (UNI) Pharma major, Ranbaxy Laboratories Ltd today said its consolidated net profit increased 53 per cent at Rs 786.60 crore for the year ended December 31, 2007 from Rs 515.4 crore last year.
For the year 2007, the company recorded consolidated sales of Rs 6,692.7 crore for 2007 against Rs 6,065.2 crore in the last calender year, registering a growth of 10 per cent.
The company has declared final dividend of Rs 6 per share for the year ended Dec 31, 2007. In November the company had declared an interim dividend of Rs 2.50 per share. This takes the total dividend for the year to Rs 8.50 per share on face value of Rs 5 each.
On a global parameter, for the year 2007, consolidated sales stood at 1,619 million dollars, an increase of 21 per cent in dollar terms.
The Company said its sales witnessed a further shift towards the high growth and more profitable branded emerging markets. These emerging markets contributed 54 per cent of global sales as against 49 per cent in the previous year and recorded a robust growth of 32 per cent.
Developed markets stood at 40 per cent of global sales and grew by 13 per cent.
The key countries in emerging markets that contributed to performance were India, CIS, Romania, South Africa and Brazil, whereas, the developed markets were led by a stronger performance from the countries in Western Europe and Canada.
UNI MP PBB AS1625